Natera (NTRA) Q2 Revenue Jumps 32%

Natera (NASDAQ:NTRA), a leader in genetic testing across oncology, women's health, and organ health, reported its earnings for Q2 2025 on August 7, 2025. The most significant news was a 32.2% year-over-year revenue increase, rising to $546.6 million (GAAP) and outpacing analyst expectations by $70.3 million or 14.8% (GAAP). However, earnings per share (GAAP) were $(0.74), missing the consensus estimate of $(0.62) (GAAP), driven by elevated legal accruals and changes to stock-based compensation. Management also raised annual revenue guidance by $80 million at the midpoint, increasing the 2025 annual revenue outlook from $1.94 billion–$2.02 billion to $2.02 billion–$2.10 billion, reflecting confidence in continued adoption of its core product lines. Overall, the quarter combined record revenue and margin expansion with heavier operating expenses, resulting in a net loss (GAAP) that widened from the same period last year. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Natera is a molecular diagnostics company specializing in genetic testing spanning oncology (cancer testing), women’s health, and organ health. Its technology analyzes tiny fragments of DNA circulating in blood to provide insights for doctors on cancer detection, prenatal conditions, and organ transplant monitoring.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool